SAN FRANCISCO--(BUSINESS WIRE)--Counsyl, a health technology company that offers DNA testing for diseases that can impact men, women and their children, today announced that Ted Snelgrove has joined the company as Chief Business Officer. With more than 25 years of commercial, product management and team leadership experience, Mr. Snelgrove will be responsible for driving product management and commercial strategies for Counsyl.
“As we've grown rapidly, Ted's experience and seasoned operating instincts are directly relevant,” said Ramji Srinivasan, cofounder and chief executive officer of Counsyl. “With his help, we can continue to scale the company to serve millions of new patients and tens of thousands of physicians.”
Mr. Snelgrove has deep experience in the molecular diagnostic sector, having built and led the original commercial team at Genomic Health that created and launched the Oncotype DX product line. He later helped build Crescendo Bioscience — now part of Myriad Genetics — where his Team developed a strong disease management franchise in rheumatology with the Vectra DA system. Ted also served as CEO at CellScape, an early player in the NIPT market. Most recently, Ted was the Oncology/Hematology Business Unit Head at Jazz Pharmaceuticals, where he led a fast growing division focused on hematologic malignancies and stem cell transplant. He got his start in the industry at Eli Lilly and progressed through commercial and strategy roles at Immunex, Amgen and ALZA. He received an MBA in Marketing from the University of Michigan and previously served as an officer in the US Navy.
“I'm excited to join Counsyl, as it aligns with my passion of being part of a high growth, mission-driven company,” said Snelgrove. “I look forward to working with the Counsyl leadership team to drive innovation that makes DNA testing more accessible. Ramji has assembled a great team and I am honored to come in at this stage and help the Company move to the next level."
Counsyl offers DNA testing for key times in people’s lives - for those starting a family, and for those at risk for inherited cancer. For more information on Counsyl, please visit www.counsyl.com.
Counsyl is a health technology company that offers DNA testing for diseases that can impact men, women and their children. The Counsyl philosophy is simple: screen for diseases where advanced knowledge makes a difference in health outcomes, whether it’s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead.
The Counsyl team includes an accomplished group of problem-solvers — top engineers, scientists, and designers — who are taking the lead on building the modern clinical laboratory. Scientific rigor, custom robotics, and software are at the heart of every Counsyl product, resulting in better, faster and more affordable screens that are broadly accessible. Beyond the laboratory, Counsyl offers doctors and patients a technology platform for results delivery in real time, with on-demand access to board-certified genetic counselors.
Counsyl has screened more than 500,000 patients and served more than 6,000 health care professionals in its CLIA-certified, CAP-accredited and NYS CLEP-permitted clinical laboratory. The company has raised a total of $102 million and is privately backed by RSTP, Goldman Sachs Asset Management, Founders Fund, Felicis Ventures, David Drummond, and other high profile investors.